公开(公告)号：US20180303888A1

公开(公告)日：2018-10-25

申请号：US15771659

申请日：2016-11-04

申请人： KOLMAR KOREA

发明人： Yong-baik CHO ,  Seul-ki KIM ,  Sang-Back KIM ,  Jae-hyuck SHIN ,  Young-ran UM ,  So-youn MOK ,  Ju-ri JUNG ,  Soon-min LIM ,  Chae Shin SEO ,  Hong Koo CHO ,  Bon Am KOO ,  Hyo Jin JEON ,  Han-Seok CHOI ,  Ye Jin KIM

IPC分类号： A61K36/285 ,  A23L33/105 ,  A61P1/00 ,  A61K36/185 ,  A61K36/9068 ,  A61K9/00

CPC分类号： A61K36/285 ,  A23L33/105 ,  A23V2002/00 ,  A61K9/0053 ,  A61K9/0056 ,  A61K36/185 ,  A61K36/28 ,  A61K36/9068 ,  A61K2236/331 ,  A61K2236/333 ,  A61P1/00

摘要： Provided is a pharmaceutical composition for preventing or treating inflammatory bowel disease (IBD) comprising a mixed extract of at least two of Aucklandia lappa Decne, Terminalia chebula Retzius, and Zingiber officinale Rosc. as an active ingredient and a method thereof, and more specifically, to a pharmaceutical composition having an inhibitory effect on monocyte adhesion in intestinal epithelial cells, an effect of inhibiting the production of inflammatory cytokines, an effect of ameliorating colitis in an animal model of dextran sodium sulfate (DSS)-induced colitis, and an effect of ameliorating Crohn's disease in an animal model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced Crohn's disease.